Interrupting the interaction between the spike protein on the SARS-CoV-2 virus and its receptor on host cells, ACE2, has become the key target of COVID-19 therapeutics. Therapeutic neutralizing antibodies achieve this, constituting a potential treatment. However, antibody production is traditionally a somewhat slow and expensive process. Now, a German group of researchers reports the rapid isolation and characterization of nanobodies from a synthetic library, known as sybodies, that target the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein.
This work is published in Nature Communications in a paper titled, “Selection, biophysical, and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2.”
To enable the virus to hook onto the cell surface, the spike protein binds ACE2 using three finger-like protrusions, called the receptor-binding domains (RBDs). Blocking the RBDs therefore has the potential to stop the virus from entering human cells. This can be done using antibodies.
Nanobodies, small antibodies found in camels and llamas, are promising as tools against viruses due to their high stability and small size. Although obtaining them from animals is time consuming, technological advances now allow for rapid selection of synthetic nanobodies, called sybodies. A technology platform to select sybodies from large synthetic libraries was recently developed in the lab of Markus Seeger, PhD, assistant professor at the University of Zurich, and made available for this study.
In search of the best sybody against SARS-CoV-2
The lab of Christian Löw, PhD, group leader at EMBL Hamburg, searched through the existing libraries to find sybodies that could block SARS-CoV-2 from infecting human cells. First, they used the viral spike protein’s RBDs as bait to select those sybodies that bind to them. Next, they tested the selected sybodies according to their stability, effectiveness, and the precision of binding. Among the best binders, one called sybody 23 turned out to be particularly effective in blocking the RBDs.
“Several binders with low nanomolar affinities and efficient neutralization activity were identified of which Sb23 displayed high affinity and neutralized pseudovirus with an IC50 of 0.6 µg/mL,” the authors wrote.
To learn exactly how sybody 23 interacts with the viral RBDs, researchers in the group of Dmitri Svergun, PhD, senior scientist at EMBL Hamburg, analyzed the binding of sybody 23 to the RBDs by small-angle X-ray scattering. In addition, Martin Hällberg, PhD, at the Karolinska Institutet used cryo-EM to determine the structure of the full SARS-CoV-2 spike bound to sybody 23.
The authors explained that the cryo-EM structure of the spike bound to sybody 23 showed that “sybody 23 binds competitively in the ACE2 binding site.” Furthermore, they noted, “the cryo-EM reconstruction revealed an unusual conformation of the spike where two RBDs are in the ‘up’ ACE2-binding conformation.”
The RBDs switch between two positions: in the “up” position the RBDs poke out, ready to bind ACE2; in the “down” position they are furled to hide from the human immune system. The molecular structures revealed that sybody 23 binds RBDs in both “up” and “down” positions, and blocks the areas where ACE2 would normally bind. This ability to block RBDs regardless of their position might explain why sybody 23 is so effective.
Finally, to test if sybody 23 can neutralize a virus, the group of Ben Murrell at Karolinska Institutet used a different virus, called a lentivirus, modified such that it carried SARS-CoV-2’s spike protein on its surface. They observed that sybody 23 successfully disabled the modified virus in vitro. Additional tests will be necessary to confirm whether this sybody could stop SARS-CoV-2 infection in the human body.
Scientific collaboration during lockdown
“The collaborative spirit has been enormous in these times, and everybody was motivated to contribute,” said Löw. The researchers started the project as soon as they received approval from EMBL leadership to reopen their laboratories during the COVID-19 lockdown. They managed to select the candidate sybodies and perform the analyses in just a few weeks.
“Getting the results so quickly was only possible because the methodologies we used had already been established for other research projects unrelated to SARS-CoV-2. Developing these tools would have taken significantly more time and resources,” said Löw.
The results of this project hold out the promise of a potential way to treat COVID-19. In future work, the scientists will perform further analyses to confirm whether sybody 23 could be an effective COVID-19 treatment.